FDA Panel to Review BPC-157 Bulk Use as Evidence Stays Limited to 30 Patients
Updated
Updated · Pharmacy Times · Jul 6
FDA Panel to Review BPC-157 Bulk Use as Evidence Stays Limited to 30 Patients
3 articles · Updated · Pharmacy Times · Jul 6
Summary
This summer, the FDA’s Pharmacy Compounding Advisory Committee will revisit whether BPC-157 can be used in bulk compounding after industry pushback against its current restriction.
Only 3 uncontrolled pilot studies covering 30 patients support the peptide, with no validated pharmacokinetics, identified receptor, or long-term human safety data for broad clinical use.
BPC-157 remains unapproved by the FDA and restricted as a Category 2 bulk drug substance, yet websites still sell it as a “research chemical,” enabling unsupervised use and variable purity.
The peptide has spread among younger fitness users through claims of faster muscle, tendon, and ligament recovery, even though WADA banned BPC-157 in 2022.
Animal studies suggest repair and anti-inflammatory effects, but reported risks—from injection-site reactions to possible cardiovascular changes and tumor-growth concerns—leave large clinical trials as the key next step.